Figure 6
Figure 6. CD23.CAR+ T lymphocytes generated from healthy donors and CLL patients produce IL-2 and proliferate in response to CD23+ tumor cells. (A-B) CD23.CAR+ T cells generated from healthy donors and CLL patients produced IL-2 when stimulated with allogeneic LCL cells (E:T ratio, 1:1) compared with NT T lymphocytes. Data represent the means ± SD for 3 and 4 different T-cell lines generated from healthy donors and CLL patients, respectively. *P ≤ .05 comparing transduced with NT T lymphocytes. (C-D) Expansion of CD23.CAR+ T cells derived from healthy donors and CLL patients in response to allogeneic LCL cells compared with NT T lymphocytes. Cells were stimulated once a week without the addition of exogenous cytokines. Data represent the means ± SD for 3 and 4 different T-cell lines generated from healthy donors and CLL patients, respectively. *P ≤ .05 comparing transduced and NT T lymphocytes.

CD23.CAR+ T lymphocytes generated from healthy donors and CLL patients produce IL-2 and proliferate in response to CD23+ tumor cells. (A-B) CD23.CAR+ T cells generated from healthy donors and CLL patients produced IL-2 when stimulated with allogeneic LCL cells (E:T ratio, 1:1) compared with NT T lymphocytes. Data represent the means ± SD for 3 and 4 different T-cell lines generated from healthy donors and CLL patients, respectively. *P ≤ .05 comparing transduced with NT T lymphocytes. (C-D) Expansion of CD23.CAR+ T cells derived from healthy donors and CLL patients in response to allogeneic LCL cells compared with NT T lymphocytes. Cells were stimulated once a week without the addition of exogenous cytokines. Data represent the means ± SD for 3 and 4 different T-cell lines generated from healthy donors and CLL patients, respectively. *P ≤ .05 comparing transduced and NT T lymphocytes.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal